4Freifeld AG, Bow E J, Sepkowitz KA, et al. Clinical practice guideline for the use of arttimicrabial agents in neutropeuic patients with cancer. 2010 update by the infectious diseases society of america[ J]. Clin In- fect Dis,2011,52(4) :56-93.
5Odoul F , Leguellec C , Lamagnere JP , et al. Prediction of metho- trexate elimination after high dose infusion in children with acute lym- phohlastic leukemia using a population pharmacokinetic approach [J]. Fundam Clin Parmacol, 1999,13:595-604.
6Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference [ J ]. Am Acad Dermatol, 2009,60(5) : 824-837.
6Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing ; Twentieth informational supplement [ S ]. CLSI/NCCLS document M100-S20. Pennsylvania : Clinical and Laboratory. Stand-ards Institute, 2010, 20-143.
7孙燕,石远凯.I临床肿瘤内科手册[M].第5版.北京:人民卫生出版社,2007.835.
8Freifeid AG, Bow E J, Sepkowitz KA, et al. Clinical practice guide- line for the use of antimierobial agents in neutropenie patients withcancer:2010 update by the Infectious Diseases Society of America[J]. Clin Infect D/s,2011,52(4) :427-431.
9Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with Iymphoproliferative disorders and solid tumours [ J ]. Eur J Cancer,2011,47( 1 ) :8-32.
10Freifeld AG,Bow E J, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Canc- er: 2010 Update by the Infectious Diseases Society of America[ J]. Clin Infect Dis ,2011,52 (4) :56-93.
